^
Association details:
| Biomarker: | ALK rearrangement + PD-L1 overepxression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | ALK inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
High PD-L1 Expression Correlates with an Immunosuppressive Tumour Immune Microenvironment and Worse Prognosis in ALK-Rearranged Non-Small Cell Lung Cancer
Published date:
06/15/2023
Excerpt:
...we collected tumour tissues from pretreated ALK-rearranged NSCLC patients....Our data showed that the median values of PFS for the high PD-L1 group and low PD-L1 group who received ALK-TKI treatment were 4.4 and 16.4 months, respectively (p = 0.008). The median overall survival (OS) of the two groups was 24.0 months and not reached, respectively (p = 0.021). Via univariate and multivariate analyses, a high PD-L1 expression and a worse ECOG PS were determined to be independent prognostic factors of OS (HR = 3.35, 95% CI: 1.23-9.11, p = 0.018; HR = 6.42, 95% CI: 1.45-28.44, p = 0.014, respectively)....High PD-L1 expression was an adverse predictive and prognostic biomarker for ALK-rearranged NSCLC.
DOI:
https://doi.org/10.3390/biom13060991
Source:
Title:
Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation
Published date:
09/08/2022
Excerpt:
...our data showed that high expression of PD-L1 (HR = 0.177, 95% CI 0.038–0.852, p = 0.027) and CTLA4 (HR = 0.196, 95% CI 0.041–0.947, p = 0.043) was related to lower OS in advanced-stage ALK- rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors (TKIs).
DOI:
https://doi.org/10.3389/fimmu.2022.974581
